Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + ramucirumab + tusamitamab ravtansine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of three agents:\n\n1. Tusamitamab ravtansine (SAR408701): An antibody-drug conjugate targeting CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5), which is expressed in non-squamous non-small cell lung cancer (NSQ NSCLC).\n\n2. Ramucirumab: A monoclonal antibody that selectively targets VEGFR2 (vascular endothelial growth factor receptor 2), inhibiting angiogenesis.\n\n3. Pembrolizumab: A PD-1 (programmed death-1) inhibitor that enhances T-cell immune responses against tumor cells.\n\nThis triple combination is being investigated for the treatment of advanced non-squamous non-small cell lung cancer (NSQ NSCLC), particularly in patients with CEACAM5-positive tumors.
- Brand names
- Keytruda
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pembrolizumab + ramucirumab + tusamitamab ravtansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + ramucirumab + tusamitamab ravtansine.